Published in Internist (Berl) on December 01, 1994
[Comments on the contribution by U. Kaboth and W. Hiddemann. Paraneoplastic syndromes]. Internist (Berl) (1995) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia (2008) 1.62
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer (2001) 1.53
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 1.52
[Ethics in medicine: needs and forms]. Internist (Berl) (1999) 1.51
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol (2003) 1.36
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer (2001) 1.32
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia (2005) 1.32
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones (2000) 1.28
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol (2001) 1.25
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol (2001) 1.21
Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood (1995) 1.20
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia (2007) 1.18
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia (2000) 1.18
Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood (2001) 1.17
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol (1985) 1.12
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia (2005) 1.12
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia (2005) 1.09
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol (1997) 1.09
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia (2009) 1.07
Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells. Ann Hematol (1998) 1.07
[Allogeneic transplantation in malignant lymphoma]. Dtsch Med Wochenschr (2001) 1.06
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant (2008) 1.05
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol (2006) 1.02
Identification of two novel, kinase-deficient variants of discoidin domain receptor 1: differential expression in human colon cancer cell lines. FASEB J (2001) 1.02
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia (2004) 1.01
Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol (1997) 1.01
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol (2001) 1.00
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer (1993) 0.99
Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood (1995) 0.99
Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta. Anticancer Drugs (1996) 0.99
Differential pattern of DNA-aneuploidy in human malignancies. Pathol Res Pract (1985) 0.99
Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination. Oncogene (2006) 0.98
DNA stemline heterogeneity in colorectal cancer. Cancer (1986) 0.98
[Pathogenesis and biology of leukemias]. Internist (Berl) (2002) 0.97
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia (2011) 0.96
Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood (1998) 0.96
[Therapeutic strategies in acute myeloid leukemia]. Internist (Berl) (2002) 0.95
Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Invest (1999) 0.95
Characterization of clone-specific rearrangement T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing. Blood (1994) 0.95
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer (2001) 0.95
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia (2002) 0.94
The long-term psychosocial effects of haematopoetic stem cell transplantation. Eur J Cancer Care (Engl) (2003) 0.94
An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas (2001) 0.94
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia (2009) 0.93
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (1999) 0.92
Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol (2001) 0.92
Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother (1992) 0.92
A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping. Leukemia (2001) 0.91
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol (2001) 0.91
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res (1997) 0.91
Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes. Leukemia (1997) 0.90
Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia (1997) 0.89
Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study. Int J Radiat Oncol Biol Phys (2000) 0.89
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group. Leukemia (1992) 0.89
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia (2005) 0.89
Subjective quality of life and sexual functioning after germ-cell tumour therapy. Br J Cancer (2003) 0.88
Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res (1998) 0.88
Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors. Int J Cancer (2000) 0.88
The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia (2011) 0.88
Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Blut (1990) 0.87
Plesiomonas shigelloides pneumonia. Med Mal Infect (2009) 0.87
Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood (1982) 0.87
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol (2001) 0.87
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia (2007) 0.87
Renin in acute myeloid leukaemia blasts. Br J Haematol (1998) 0.86
Management of infections during intensive treatment of hematologic malignancies. Ann Hematol (1997) 0.86
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer (1997) 0.86
De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia (1996) 0.86
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia. Cancer Genet Cytogenet (2001) 0.85
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol (2008) 0.85
Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer (1995) 0.85
Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia (1989) 0.85